Longitudinal Variations in Th and Treg Cells Before and After Percutaneous Coronary Intervention, and Their Intercorrelations and Prognostic Value in Acute Syndrome Patients
- PMID: 38874809
- DOI: 10.1007/s10753-024-02062-x
Longitudinal Variations in Th and Treg Cells Before and After Percutaneous Coronary Intervention, and Their Intercorrelations and Prognostic Value in Acute Syndrome Patients
Abstract
T helper (Th) and regulatory T (Treg) cells regulate atherosclerosis, plaque, inflammation to involve in acute coronary syndrome (ACS). The current study aimed to investigate the clinical implications of Th and Treg cells in ACS patients receiving percutaneous coronary intervention (PCI). Blood Th1, Th2, Th17 and Treg cells were detected in 160 ACS patients before PCI, after PCI, at 1 month (M). Short physical performance battery (SPPB) at M1/M3 and major adverse cardiac event (MACE) during follow-ups were evaluated. Th1 and Th17 both showed upward trends during PCI, then greatly declined at M1 (P < 0.001). Th2 exhibited an upward trend during PCI but decreased slightly at M1 (P < 0.001). Treg remained stable during PCI but elevated at M1 (P < 0.001). Moreover, a positive correlation between Th1 and Th17, a negative correlation between Th17 and Treg, were discovered at several timepoints (most P < 0.050). Interestingly, the receiver operating curve (ROC) analyses revealed that Th1 [area under curve (AUC) between 0.633-0.645] and Th17 (AUC between 0.626-0.699) exhibited values estimating SPPB score <= 6 points at M1 or M3 to some extent. Importantly, Th1 (AUC between 0.708-0.710), Th17 (AUC between 0.694-0.783), and Treg (AUC between 0.706-0.729) predicted MACE risk. Multivariate models involving Th and Treg cells along with other characteristics revealed acceptable values estimating SPPB score <= 6 points at M1 or M3 (AUC between 0.690-0.813), and good values predicting MACE risk (AUC between 0.830-0.971). Dynamic variations in Th and Treg cells can predict the prognosis of ACS patients receiving PCI.
Keywords: MACE risk; T helper and regulatory T cells; acute coronary syndrome; percutaneous coronary intervention; short physical performance battery.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing Interests: The authors declare no competing interests.
Similar articles
-
Serum brain-derived neurotrophic factor in coronary heart disease: Correlation with the T helper (Th)1/Th2 ratio, Th17/regulatory T (Treg) ratio, and major adverse cardiovascular events.J Clin Lab Anal. 2023 Jan;37(1):e24803. doi: 10.1002/jcla.24803. Epub 2022 Dec 12. J Clin Lab Anal. 2023. PMID: 36510348 Free PMC article.
-
Intensive statin treatment ameliorate the Th17/Treg functional imbalance in patients with non-ST elevation acute coronary syndrome underwent percutaneous coronary intervention.Clin Cardiol. 2020 Apr;43(4):379-385. doi: 10.1002/clc.23326. Epub 2019 Dec 24. Clin Cardiol. 2020. PMID: 31872906 Free PMC article. Clinical Trial.
-
Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome.Atherosclerosis. 2011 Aug;217(2):518-24. doi: 10.1016/j.atherosclerosis.2011.03.043. Epub 2011 Apr 9. Atherosclerosis. 2011. PMID: 21524750
-
The Th17/Treg imbalance in patients with acute coronary syndrome.Clin Immunol. 2008 Apr;127(1):89-97. doi: 10.1016/j.clim.2008.01.009. Epub 2008 Feb 21. Clin Immunol. 2008. PMID: 18294918
-
The role of oxidized low-density lipoprotein in breaking peripheral Th17/Treg balance in patients with acute coronary syndrome.Biochem Biophys Res Commun. 2010 Apr 9;394(3):836-42. doi: 10.1016/j.bbrc.2010.03.090. Epub 2010 Mar 17. Biochem Biophys Res Commun. 2010. PMID: 20302843
References
-
- Bergmark, B.A., N. Mathenge, P.A. Merlini, M.B. Lawrence-Wright, and R.P. Giugliano. 2022. Acute coronary syndromes. Lancet 399 (10332): 1347–1358. https://doi.org/10.1016/S0140-6736(21)02391-6 . - DOI - PubMed - PMC
-
- Bhatt, D.L., R.D. Lopes, and R.A. Harrington. 2022. Diagnosis and treatment of acute coronary syndromes: A Review. JAMA 327 (7): 662–675. https://doi.org/10.1001/jama.2022.0358 . - DOI - PubMed
-
- Hoole, S.P., and P. Bambrough. 2020. Recent advances in percutaneous coronary intervention. Heart 106 (18): 1380–1386. https://doi.org/10.1136/heartjnl-2019-315707 . - DOI - PubMed
-
- Ozaki, Y., H. Hara, Y. Onuma, Y. Katagiri, T. Amano, T. Kobayashi, T. Muramatsu, H. Ishii, K. Kozuma, N. Tanaka, H. Matsuo, S. Uemura, K. Kadota, Y. Hikichi, K. Tsujita, J. Ako, Y. Nakagawa, Y. Morino, I. Hamanaka, N. Shiode, J. Shite, J. Honye, T. Matsubara, K. Kawai, Y. Igarashi, A. Okamura, T. Ogawa, Y. Shibata, T. Tsuji, J. Yajima, K. Iwabuchi, N. Komatsu, T. Sugano, M. Yamaki, S. Yamada, H. Hirase, Y. Miyashita, F. Yoshimachi, M. Kobayashi, J. Aoki, H. Oda, Y. Katahira, K. Ueda, M. Nishino, K. Nakao, I. Michishita, T. Ueno, T. Inohara, S. Kohsaka, T.F. Ismail, P.W. Serruys, M. Nakamura, H. Yokoi, Y. Ikari, Task Force on Primary Percutaneous Coronary Intervention of the Japanese Cardiovascular Interventional T. 2022. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022. Cardiovascular Intervention and Therapeutics 37 (1): 1–34. https://doi.org/10.1007/s12928-021-00829-9 . - DOI - PubMed - PMC
-
- Faro, D.C., C. Laudani, F.G. Agnello, N. Ammirabile, S. Finocchiaro, M. Legnazzi, M.S. Mauro, P.M. Mazzone, G. Occhipinti, C. Rochira, L. Scalia, M. Spagnolo, A. Greco, and D. Capodanno. 2023. Complete percutaneous coronary revascularization in acute coronary syndromes with multivessel coronary disease: a systematic review. JACC. Cardiovascular Interventions 16 (19): 2347–2364. https://doi.org/10.1016/j.jcin.2023.07.043 . - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous